Drug Design, Development and Therapy has retracted a 2013 paper by a group from Italy for duplication.
The retraction notice for the paper, “Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome,” fairly bristles with indignation: Continue reading Cancer-anorexia paper retracted for “unacceptable” duplication
Two cancer researchers who hold a patent on a particular pathway that might be a target for new drugs — and one of whom leads a company that is studying those potential drugs — have retracted two related papers in the Journal of Biological Chemistry (JBC).
The notices for “Kinase suppressor of Ras signals through Thr269 of c-Raf-1” and “The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK,” which share H. Rosie Xing and Memorial Sloan-Kettering’s Richard Kolesnick as authors, say the same thing: Continue reading Cancer researchers retract two papers in the JBC
The journal Case Reports in Medicine has retracted a 2012 article by a group of Turkish authors who made up things in the piece.
The paper, “Brain Metastasis as an Initial Manifestation of Ovarian Carcinoma: A Case Report,” came from ob-gyns at Hacettepe University in Ankara, and purported to relate the case of
A 30-year-old gravida 2, para 2 woman admitted to our hospital with complaints of headache, nausea, vomiting, and right-sided blurred vision. She did not report any previous medical history or malignancy. Her neurologic examination revealed a right optic disc edema suggesting a posterior orbital mass. Her cranial computerized tomography (CT) scan showed multiple lesions that are a 6 mm mass on the right parietal lobe, a 16 mm mass on the left occipital, and another 7 mm mass on the left temporal lobe (Figures 1 and 2). All the lesions were hyperintense and surrounded by edema which suggests a metastatic cancer. Her cranial magnetic resonance imaging (MRI) also confirmed similar findings suggestive of a metastatic cancer to the brain. Continue reading Case report journal pulls paper on metastatic ovarian cancer with falsified data
The first retraction has appeared for Alfred Fusco, a leading cancer researcher in Italy under criminal investigation for fraud.
Here’s the notice from the Journal of Clinical Investigation: Continue reading Retraction appears for Italian cancer specialist facing criminal investigation
The Journal of Biological Chemistry has a fairly gory correction — we’d call it a mega-correction — for a 2010 paper by Levon Khachigian, an Australian researcher whose studies of a new drug for skin cancer recently were halted over concerns about possible misconduct, including image manipulation. As we reported earlier this year, Khachigian has already lost four papers, including one in the JBC — which the journal simply noted had “been withdrawn by the authors.”
The new correction involves the article “c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins,” which Khachigian wrote with Jun Ni and Alla Waldman. The paper has been cited nine times, according to Thomson Scientific’s Web of Knowledge. Here’s the notice: Continue reading JBC issues correction for paper by Khachigian, who has had four others retracted
A leading Neapolitan cancer researcher is under criminal investigation for fraud, the Italian press is reporting.
Although we have only rough translations of the story, it seems the researcher, Alfredo Fusco, of the National Council of Research’s Institute of Experimental Endocrinology and Oncology, has been accused of manipulating images in published studies and to strengthen the case for grants from the Italian Association for Cancer Research (AIRC).
The case covers eight papers published between 2001 and 2012, according to the media reports. We don’t know the specifics of the eight articles, nor why none appears yet to have been retracted. In our experience, the criminal inquiries usually follow the expose of scientific misconduct, not the other way around.
Fusco’s work is highly cited, with some 50 papers cited at least 100 times, according to Thomson Scientific’s Web of Knowledge.
According to the institute’s website: Continue reading Italian cancer specialist facing criminal investigation for misconduct
At team of researchers at MD Anderson Cancer Center has retracted a paper after realizing that the cell lines they were using weren’t what they thought they were.
Here’s the detailed notice: Continue reading Cancer cell line mixup leads to retraction
A group of researchers at the Einstein College of Medicine in the Bronx, New York has retracted two papers for image manipulation.
The retraction notices for “PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase” and “The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab” say the same thing: Continue reading Papers on potential cancer drugs retracted for image manipulation
The fifth of six expected retractions for copyright infringement has arrived for a group of sex researchers led by Willibrord Weijmar Schultz, this one in the International Journal of Gynecological Cancer of a 1992 article.
As we reported earlier this year, Schultz (whose 1999 paper on sex in an MRI won an Ig Nobel prize) and his colleague, Mels F. Van Driel, were found not to have committed plagiarism by investigators at the University of Groningen. Instead, they were found guilty of “unintended and unknowing breach of copyright.”
But they were asked to apologize formally to a litany of people — from the editors involved to the sponsors of the research — for what the institution described as “unintended and unknowing breach of copyright” of the work of one Diana Jeffrey, whose 1985 dissertation evidently was very much worth reading.
Here’s the latest retraction notice: Continue reading One more paper down for sex researcher Weijmar Schultz
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).